present
deliveri
antigen
crucial
induc
immun
desir
lifelong
protect
recombin
viral
vectorsproven
safe
success
veterinari
vaccin
applicationsar
ideal
shuttl
deliv
foreign
protein
induc
immun
respons
protect
antibodi
level
mimick
natur
infect
exampl
viral
vector
adenovirus
measl
viru
poxvirus
requir
attribut
qualifi
vaccin
vector
follow
stabl
insert
code
sequenc
genom
induct
protect
immun
respons
proven
safeti
record
potenti
largescal
product
need
develop
new
vaccin
infecti
diseas
increas
vaccin
access
reduc
health
cost
simplifi
overload
immun
schedul
driven
idea
combin
antigen
variou
pathogen
protect
effect
vaccin
requir
multipl
antigen
one
pathogen
differ
pathogen
serotypesserogroup
combin
multival
polyval
vaccin
futur
multival
vaccin
candid
like
requir
complex
diseas
like
malaria
hiv
novel
strategi
propos
antigen
combin
differ
pathogen
protect
sever
diseas
multidiseas
multipathogen
vaccin
singl
vaccin
agent
envisag
simultan
protect
sever
common
global
pathogen
employ
wellestablish
safe
vector
costeffect
unifi
program
underli
principl
genet
engin
vaccin
design
may
appli
prevent
infect
problem
protect
host
multipl
serotyp
genotyp
address
also
import
recogn
elicit
protect
cytotox
lymphocyt
respons
epitop
within
conserv
viral
protein
anoth
mean
end
viral
vector
vaccin
appli
extens
veterinari
medicin
although
discuss
detail
minireview
outstand
exampl
rabor
vrg
merial
first
oral
live
vaccinia
viru
vacv
vector
vaccin
express
glycoprotein
gp
evelynrokitnickiabelseth
rabi
viru
introduct
rabi
control
wildlif
reli
mostli
depopul
vaccin
individu
anim
rabor
vrg
allow
oral
vaccin
larg
scale
use
vaccinecontain
bait
sever
countri
use
rabor
vrg
safe
without
advers
effect
achiev
complet
rabi
control
hurdl
taken
introduc
viral
vector
vaccin
candid
human
appreci
higher
anim
thu
develop
human
viral
vaccin
licens
remain
behind
achiev
anim
vaccin
pressur
find
vaccin
diseas
caus
widespread
epidem
recent
ebola
outbreak
acceler
effort
fast
track
viral
vaccin
candid
human
promis
exampl
like
ebola
vaccin
base
recombin
adenoviru
modifi
vaccinia
ankara
mva
may
mark
advent
first
new
gener
viral
vaccin
use
human
develop
new
combin
vaccin
requir
reflect
terminolog
current
use
describ
new
class
chimer
vaccin
review
relev
literatur
reveal
problemat
ambigu
definit
term
multival
polyval
vaccin
ambigu
use
describ
either
vaccin
candid
abil
protect
sever
diseas
vaccin
candid
protect
sever
strain
singl
pathogen
gener
parlanc
multivalentpolyval
refer
agent
effect
differ
type
organ
accord
terminolog
infect
consist
multipl
pathogen
gener
describ
multipathogen
diseas
simpli
multidiseas
avoid
confus
follow
nomenclatur
propos
distinguish
differ
type
combin
vaccin
multivalentpolyval
vector
vaccin
combin
antigen
differ
strain
serotypesserogroup
one
pathogen
singl
vector
immun
one
diseas
multidiseasemultipathogen
vector
vaccin
key
protect
antigen
two
pathogen
singl
vector
immun
sever
diseas
figur
show
schemat
overview
multivalentpolyval
multipathogenmultidiseas
viral
vector
minireview
detail
exist
multipathogen
multival
vaccin
deriv
viral
vector
draw
distinct
simpl
multipathogen
vaccin
vector
form
part
protect
agent
exampl
recombin
vaccinia
virus
theoret
current
irrelev
potenti
induc
immun
smallpox
vector
backbon
vehicl
deliv
protect
two
addit
pathogen
anoth
possibl
gener
multipathogen
multival
vaccin
base
vector
protect
antigen
replac
antigen
deriv
heterolog
virus
vaccin
like
yield
protect
heterolog
viru
protect
yield
vector
agent
like
impair
vaccin
candid
discuss
minireview
also
compar
contrast
larger
viral
vector
like
serv
backbon
futur
broadspectrum
multipathogen
multival
vaccin
address
technolog
hurdl
remain
human
vaccin
becom
wide
distribut
tabl
provid
overview
current
multival
multipathogen
viral
vector
vaccin
investig
wide
varieti
virus
investig
singlepathogen
vector
vaccin
remark
fewer
use
multival
multipathogen
applic
virus
meet
sever
requir
consid
suitabl
multipathogen
multival
vector
viral
vector
capabl
take
larg
fragment
immunogen
gene
togeth
regulatori
element
eg
promot
polymeras
termin
etc
immunomodul
like
cytokin
enhanc
humor
cellular
immun
respons
need
express
effici
stabli
sometim
differ
loci
within
genom
prefer
without
persist
recombin
viru
host
integr
host
genom
factor
consid
choos
vector
platform
lack
toxic
host
afford
largescal
product
issu
preexist
vector
immun
may
lead
reduc
immun
respons
vector
tabl
compar
viral
vector
discuss
articl
respect
individu
vector
characterist
suitabl
multivalentmultipathogen
viral
vector
candid
measl
viru
among
viral
vector
platform
measl
viru
mv
promis
candid
measl
viru
exclus
human
pathogen
envelop
viru
famili
paramyxovirida
singlestrand
negativesens
rna
genom
sever
mv
strain
eg
moraten
schwarz
edmonston
measl
viru
vaccin
strain
safe
use
vaccin
mani
year
exhibit
strong
immunogen
properti
lead
lifelong
protect
mv
replic
occur
strictli
cytoplasm
infect
cell
contribut
consist
safeti
profil
viral
dna
integr
host
genom
abil
achiev
stabl
insert
nucleotid
mv
genom
unlik
rna
virus
togeth
effici
express
transgen
low
product
cost
make
mv
valuabl
potenti
vaccin
deliveri
system
mani
multipathogen
vaccin
candid
base
measl
viru
vector
viru
use
immunogen
one
exampl
mv
vector
moraten
berna
measl
vaccin
strain
sequenc
human
papillomaviru
hpv
vaccin
candid
gener
cantarella
colleagu
prove
induc
strong
humor
immun
respons
mv
hpv
transgen
interferon
alpha
receptordefici
ifnar
mice
revers
genet
technolog
enabl
rescu
mv
rna
viru
clone
plasmid
dna
contain
mv
antigenom
cell
cultur
use
human
helper
cell
line
structur
protein
sequenc
found
immunogen
previou
studi
insert
p
sequenc
mv
form
viruslik
particl
express
stabil
transgen
express
import
factor
success
vaccin
candid
test
passag
cell
human
fetal
lung
fibroblast
show
reduct
furthermor
recombin
exhibit
reduc
growth
kinet
compar
empti
mv
immunogen
activ
evalu
murin
immun
studi
mvsuscept
mice
ifnar
devoid
interferon
type
receptor
plu
express
human
mice
inject
intraperiton
parent
mv
day
week
later
pfu
mice
immun
mount
humor
immun
respons
compar
humor
immun
respons
elicit
mice
three
intramuscular
inject
standard
hpv
vaccin
cervarix
glaxosmithklin
biolog
cervarix
licens
viruslik
particl
vaccin
diseas
associ
viruslik
particl
obtain
baculoviru
express
system
serum
immun
mice
also
examin
antimeasl
viru
antibodi
differ
immun
respons
mv
observ
recombin
viru
compar
parent
mv
mv
capac
larger
insert
kb
vector
may
exploit
express
immunogen
hpv
type
eg
addit
author
suggest
insert
protein
may
allow
vaccin
candid
use
immunotherapi
anoth
approach
brandler
et
al
recombin
measl
vaccin
express
chikungunya
viruslik
particl
gener
use
helper
cell
line
rescu
approach
chikungunya
viru
chikv
alphaviru
posit
rna
genom
transmit
mosquito
especi
southeast
asia
africa
indian
subcontin
recent
year
tendenc
viru
spread
temper
region
measl
viru
schwarz
strain
use
insert
phosphoprotein
matrix
gene
mv
c
structur
protein
sequenc
chikv
la
reunion
strain
account
epidem
worldwid
transgen
mice
suscept
measl
infect
inject
intraperiton
two
consecut
dose
rang
tissu
cultur
infect
dose
tcid
month
apart
control
group
receiv
empti
mv
schwarz
strain
mice
vaccin
mvchikv
show
gener
specif
antibodi
mv
vector
chikv
well
specif
cellular
immun
assay
splenocyt
boost
second
immun
furthermor
plaqu
reduct
neutral
test
show
chikvneutr
antibodi
induc
challeng
studi
month
last
inject
pfu
chikv
equal
time
lethal
concentr
ld
intraperiton
inject
perform
mice
immun
tcid
mvchikv
complet
protect
chikv
even
preexist
immun
mv
mice
immun
geometr
mean
titer
neutral
antibodi
blood
particip
lower
low
dose
priorix
vaccin
group
medium
high
dose
group
nevertheless
group
show
seroconvers
booster
immun
impact
preexist
antimeasl
immun
mvchikv
vaccin
candid
investig
found
impact
perform
vaccin
candid
author
conclud
phase
clinic
trial
warrant
evalu
promis
vaccin
candid
adenoviru
adenovirus
adv
wide
studi
vector
gene
therapi
vaccin
target
variou
diseas
malaria
hepat
c
sever
characterist
make
attract
vaccin
vector
includ
manufactur
abil
elicit
broad
immun
respons
adenovirus
doublestrand
dna
dsdna
virus
replic
nuclei
vertebr
easili
manipul
take
foreign
dna
kb
cultiv
sever
cell
type
divid
nondivid
cell
well
dendrit
cell
produc
high
viru
titer
high
level
protein
express
express
level
even
enhanc
use
heterolog
promot
anoth
advantag
adv
abil
induc
strong
tcell
respons
includ
cytotox
cell
howev
preexist
vector
immunitya
present
larg
proport
individualsinhibit
effici
express
transgen
inactiv
viral
vector
potenti
altern
nonhuman
adv
vector
engin
vector
adenovir
vector
avail
replic
defici
compet
mammalian
cell
gener
multival
ebola
viru
ebov
vaccin
employ
adv
platform
pioneer
wang
colleagu
creat
bival
complex
adenovirusbas
vaccin
cadvax
vector
util
complex
adenoviru
technolog
carri
gp
ebola
viru
sudan
bonifac
strain
sebov
zair
strain
zebov
cadvax
vector
replicationdefect
adenoviru
vector
platform
delet
gene
enabl
vector
accommod
larg
amount
foreign
dna
balbc
mice
immun
intraperiton
pfu
bival
vaccin
candid
week
cadvax
sz
vaccin
candid
abl
induc
sebov
ebov
ebolaspecif
antibodi
strain
respons
well
cellmedi
immun
respons
investig
cadvax
sz
vaccin
candid
protect
mice
lethal
challeng
mouseadapt
ebola
viru
strain
zebovderiv
balbc
mice
immun
subcutan
inject
pfu
bival
vaccin
candid
day
follow
challeng
pfu
mouseadapt
ebola
viru
intraperiton
vaccin
anim
protect
basi
work
swenson
colleagu
develop
multistrain
filoviru
vaccin
util
complex
adenoviru
technolog
adenoviru
vector
cadvax
filovirida
primarili
ebola
viru
marburg
viru
caus
sever
diseas
human
nonhuman
primat
high
diverg
speci
lack
crossprotect
make
vaccin
develop
difficult
task
panfiloviru
vaccin
approach
compris
antigen
zair
ebola
viru
zebov
sudan
ebola
viru
sebov
ravn
musok
strain
marburg
viru
marv
four
differ
cadvax
vector
design
vector
contain
two
copi
nucleoprotein
np
zebov
vector
express
glycoprotein
gp
ebov
sebov
vector
express
ravn
gp
vector
express
musok
gp
np
gene
four
vector
portion
equal
pfu
one
combin
vaccin
inject
intramuscularli
cynomolgu
macaqu
day
booster
vaccin
day
vaccin
anim
challeng
time
lethal
dose
marv
follow
ebov
vice
versa
vaccin
primat
protect
zebov
sebov
well
three
marburg
viru
speci
ravn
musok
concord
studi
pratt
colleagu
report
multival
ebola
viru
vaccin
candid
base
cadvax
system
express
glycoprotein
sebov
bonifac
strain
zebov
kikwit
strain
furthermor
marburg
viru
ravn
gp
design
studi
includ
immun
cynomolgu
macaqu
equal
mixtur
pfu
administ
intramuscularli
day
boost
day
led
similar
level
antibodi
zebov
sebov
simultan
administr
vaccin
candid
interfer
level
antibodi
gener
zebov
sebov
test
whether
bival
vaccin
candid
protect
vaccin
anim
ebola
viru
diseas
macaqu
challeng
intramuscularli
pfu
zebov
pfu
sebov
pfu
sebov
follow
pfu
zebov
vaccin
macaqu
surviv
lethal
challeng
without
develop
sign
diseas
author
investig
whether
vaccin
candid
confer
protect
aerosol
challeng
pfu
aerosol
sebov
pfu
aerosol
sebov
vaccin
pfu
day
vaccin
protect
vaccin
macaqu
aerosol
challeng
either
viru
otherwis
lethal
dose
even
preexist
vector
immun
adenovir
vector
data
recombin
administ
simultan
would
interest
investig
whether
coadministr
protect
macaqu
challeng
respect
marburg
viru
speci
base
result
report
swenson
colleagu
macaqu
surviv
challeng
time
lethal
dose
marv
seem
like
author
suggest
similar
protect
marv
may
achiev
need
investig
futur
administr
multipl
viral
vector
simultan
evalu
care
viral
vector
harbor
potenti
risk
unintend
recombin
event
eg
viral
vector
vaccin
natur
occur
virus
host
may
lead
hybrid
speci
unknown
characterist
use
replicationdefect
vector
reduc
risk
may
elimin
complet
varicellazost
viru
varicellazost
viru
vzv
endem
worldwid
infect
rate
high
adolesc
first
vaccin
vzv
develop
earli
current
use
vaccin
atc
code
http
wwwwhoccnoatcdddindex
code
consist
live
attenu
vzv
monitor
year
demonstr
high
safeti
profil
minor
side
effect
healthi
peopl
besid
host
rang
vzv
restrict
human
obstruct
uncontrol
environment
spread
safeti
opportun
insert
maintain
larg
dna
insert
combin
abil
induc
strong
cellular
humor
immun
spark
interest
use
recombin
vaccin
candid
gener
multival
multipathogen
vaccin
matsuura
colleagu
report
success
applic
vzv
vaccin
vector
introduc
two
major
surfac
protein
mump
viru
muv
hemagglutininneuraminidas
hn
fusion
protein
vzv
voka
strain
use
bacteri
artifici
chromosom
bac
system
integr
membran
protein
hn
respons
receptor
bind
host
cell
muv
neuraminidas
hemagglutinin
activ
wherea
f
protein
main
activ
lie
viral
penetr
hemolysi
recombin
vokahnf
exhibit
reduc
growth
kinet
atyp
cytopathogen
effect
syncytium
format
lead
cell
detach
cell
human
fetal
lung
fibroblast
cell
effect
overcom
introduc
mutat
serinetotyrosin
substitut
prevent
membran
fusion
guinea
pig
immun
four
time
subcutan
cell
infect
either
vaccin
candid
interv
vaccin
candid
induc
neutral
antibodi
vzv
vector
anim
immun
vzv
vokahnf
mount
slightli
higher
titer
neutral
antibodi
muv
induc
higher
group
vaccin
slight
differ
immun
respons
recombin
construct
observ
data
suggest
vzv
strong
candid
futur
multival
multipathogen
vaccin
develop
may
advis
use
viral
vector
cautious
replic
compet
human
host
parainfluenza
virus
nonseg
negativestrand
rna
virus
genom
size
roughli
nucleotid
easili
manipul
attenu
revers
genet
see
also
mv
viral
replic
take
place
cytoplasm
host
need
integr
genom
recombin
event
rare
piv
contribut
stabil
insert
transgen
second
lead
caus
hospit
viral
respiratori
tract
diseas
develop
vaccin
encourag
particularli
combin
alreadi
establish
vaccin
facilit
implement
routin
vaccin
schedul
parenter
administ
standard
mv
vaccin
harbor
risk
neutral
first
month
life
serum
antibodi
passiv
transfer
mother
babi
new
mv
vaccin
candid
bypass
would
valuabl
asset
infant
vaccin
schedul
therefor
combin
vaccin
strategi
includ
piv
mv
suggest
viral
backbon
gener
wildtyp
recoveri
plasmidborn
cdna
use
recombin
dna
technolog
attenu
version
wildtyp
develop
eg
shown
promis
result
vaccin
candid
studi
hemagglutinin
ha
protein
mv
edmonston
strain
insert
attenu
n
p
gene
p
gene
hn
l
gene
vaccin
candid
induc
antibodi
mv
golden
syrian
hamster
especi
insert
np
pm
junction
signific
differ
neutral
antibodi
observ
use
attenu
compar
use
wildtyp
viru
challeng
experi
wildtyp
took
place
day
intranas
immun
pfu
vaccin
candid
confer
signific
protect
viral
replic
respiratori
tract
previou
studi
monkey
suggest
abl
replic
effici
even
presenc
passiv
acquir
antibodi
lead
conclus
even
preexist
matern
mv
antibodi
intranas
administ
vaccin
may
protect
author
report
recombin
vaccin
candid
elicit
averag
five
time
serum
antibodi
licens
live
attenu
measl
viru
vaccin
administ
intramuscular
inject
also
suggest
employ
antigen
serotyp
eg
prime
boost
vaccin
reduc
risk
vector
immun
effici
transgen
express
coxsackieviru
group
b
coxsackievirus
positivesens
singlestrand
rna
ssrna
virus
six
serotyp
group
b
coxsackieviru
describ
particularli
identifi
potenti
vaccin
vector
cvb
incorpor
four
capsid
protein
seven
nonstructur
protein
includ
two
proteas
although
small
genom
somewhat
limit
capac
stabli
integr
foreign
genet
materi
cvb
interest
viral
vector
candid
strong
immun
respons
cellular
humor
gener
follow
infect
coxsackievirus
known
caus
gastrointestin
distress
myocard
dilat
cardiomyopathi
human
togeth
cvb
human
adenoviru
type
regularli
link
heart
diseas
date
vaccin
either
viru
commerci
avail
protect
human
heart
diseas
hofl
colleagu
investig
chimer
vaccin
candid
express
antigen
loop
hexon
protein
loop
produc
promis
result
rabbit
model
locu
capsid
protein
proteas
genom
insert
sequenc
express
passag
hela
cell
howev
viru
speci
correspond
parent
strain
detect
passag
indic
recombin
viru
unstabl
reduc
viru
titer
comparison
parent
strain
observ
suggest
insert
lead
attenu
viral
vector
investig
potenti
vaccin
candid
gener
humor
immun
respons
murin
immunogen
studi
perform
balbc
mice
inject
intraperiton
tcid
twice
three
time
interv
result
show
vaccin
candid
abl
induc
hexon
loopneutr
bind
antibodi
titer
increas
number
booster
inject
interestingli
preexist
anticvb
antibodi
boost
immun
respons
led
even
higher
level
antibodi
mice
receiv
three
inject
multipathogen
vaccin
candid
evalu
immun
respons
time
determin
durat
protect
necessari
also
interest
determin
whether
crossprotect
cvb
serotyp
achiev
candid
vaccin
although
recombin
viru
induc
neutral
bind
antibodi
insert
vector
mous
model
question
use
would
feasibl
human
applic
due
issu
encount
insert
instabl
moreov
even
though
mous
studi
show
viru
inhibit
preexist
antibodi
need
evalu
prove
true
coxsackieviru
serotyp
poxvirusmodifi
vaccinia
ankara
famili
poxvirida
divid
two
subfamili
chordopoxvirina
entomopoxvirina
within
subfamili
chordopoxvirina
genu
orthopoxviru
includ
variola
viru
caus
agent
smallpox
interest
human
vaccin
research
wide
use
candid
new
vaccin
design
vaccinia
viru
vacv
viru
exhibit
uniqu
featur
qualifi
use
effect
express
system
ideal
recombin
vector
larg
genom
size
vacv
kbp
allow
insert
larg
amount
foreign
dna
kb
homolog
recombin
direct
clone
bacteri
artifici
chromosom
technolog
characterist
enabl
design
vaccin
multipl
pathogen
within
singl
express
system
vaccinia
viru
also
appli
via
differ
rout
inject
oral
induc
longlast
immun
mani
far
unsuccess
effort
develop
vaccin
complex
diseas
tuberculosi
malaria
requir
present
one
antigen
potenti
overcom
poxvir
antigen
present
platform
life
cycl
vacv
fulli
accomplish
cellular
cytoplasm
requir
integr
viral
genet
materi
genom
host
attribut
absenc
latent
stage
viral
infect
cycl
advantag
vaccin
design
extens
investig
vacv
promis
candid
vaccin
design
led
number
modifi
vacv
strain
higher
safeti
profil
effici
express
system
higher
immunogen
host
among
poxvirus
eg
fowlpox
canarypox
new
york
vaccinia
viru
promis
candid
vaccin
design
attenu
vaccinia
strain
modifi
vaccinia
ankara
mva
rel
parent
strain
chorioallanto
vaccinia
ankara
mva
lost
bp
genet
inform
six
major
delet
site
attenu
process
delet
site
shown
function
insert
site
foreign
gene
mva
genom
foreign
gene
also
insert
upstream
endogen
poxvir
promot
situ
fear
next
influenza
pandem
driven
effort
toward
develop
novel
vaccin
highli
pathogen
avian
influenza
type
heterolog
influenza
strain
seem
rise
prabakaran
colleagu
develop
univers
vaccin
candid
broad
coverag
pandem
prepared
ha
gene
strain
select
base
neutral
epitop
ha
cover
variant
clade
three
insert
delet
site
mvator
emerg
biosolut
gaithersburg
md
usa
control
separ
promot
psyni
psynii
result
trival
mvatortriha
control
rmvator
carri
gene
construct
mice
balbc
immun
intramuscularli
twostep
protocol
day
day
l
tcid
mvatortriha
exhibit
signific
hemagglutin
inhibit
titer
homolog
virus
heterolog
clade
wherea
monoval
candid
induc
poor
hemagglutin
inhibit
titer
challeng
experi
ten
minim
lethal
dose
mld
intranas
homolog
clade
heterolog
clade
viru
show
mvtortriha
vaccin
candid
confer
complet
protect
weight
loss
death
immun
mice
contrast
previou
experi
shown
monoval
counterpart
confer
protect
homolog
strain
crossclad
immun
heterolog
clade
confirm
serolog
surveil
studi
guinea
pig
vaccin
trival
vaccin
candid
author
conclud
robust
broadli
neutral
activ
mvatortriha
vaccin
candid
may
also
protect
yet
unknown
strain
poxvir
vector
seem
excel
deliveri
vehicl
proven
safe
effici
mani
monoval
recombin
vaccin
candid
number
vaccin
grow
prevent
rather
treatment
effect
mean
control
viru
infect
combin
vaccin
becom
import
protect
sever
diseas
fewer
inject
maintain
efficaci
safeti
singlecompon
vaccin
help
reduc
cost
health
servic
patient
also
simplifi
vaccin
schedul
despit
progress
infecti
diseas
still
claim
million
live
everi
year
mani
includ
malaria
leishmania
hiv
tuberculosi
vaccin
develop
produc
suboptim
protect
thu
far
viral
vector
potenti
overcom
uniqu
way
antigen
present
capac
express
variou
transgen
countri
ineffect
health
servic
combin
vaccin
would
easier
administ
individu
counterpart
immun
coverag
could
achiev
easili
fewer
visit
medic
center
result
lower
mortal
lower
treatment
cost
lower
level
residu
morbid
postinfect
among
new
vaccin
product
polyval
multipathogen
viral
vector
vaccin
hold
great
promis
advantag
recombin
vaccin
includ
abil
deliv
multipl
immunogen
cell
vaccine
guarante
effici
express
conveni
mani
viral
vector
shuttl
present
protein
immun
system
way
occur
natur
infect
cycl
therefor
ensur
potent
induct
cellular
humor
immun
respons
rout
antigen
present
hold
promis
longlast
protect
without
numer
booster
vaccin
mani
current
use
vector
modifi
vaccinia
ankara
measl
viru
vaccin
use
year
accumul
signific
safeti
efficaci
data
clinic
laboratori
research
use
prior
vaccin
applic
progress
genet
engin
recombin
dna
technolog
improv
express
system
promot
termin
enhanc
etc
advanc
field
recombin
vaccin
design
use
multipathogen
multival
vaccin
special
attent
must
paid
interact
variou
compon
potenti
interact
includ
antagonist
synergist
effect
antigen
competit
andor
epitop
suppress
result
inappropri
immun
respons
common
percept
vaccin
contain
one
antigen
overburden
immun
system
studi
shown
immun
system
respons
million
antigen
vaccin
contain
specif
antigen
overload
function
immun
system
clearli
extrem
unlik
anoth
challeng
need
address
manufactur
test
new
formul
compon
vaccin
must
assess
individu
combin
standard
test
stabil
steril
potenc
efficaci
etc
ensur
consist
product
addit
complex
vaccin
emerg
regulatori
agenc
need
introduc
new
polici
provid
guidelin
research
manufactur
practition
regard
test
licens
document
inform
market
vaccin
enorm
potenti
viral
vector
vaccin
drive
continu
develop
novel
express
vector
rhabdovirusor
influenza
virusbas
platform
latest
suggest
potenti
express
variou
antigen
insert
variou
transgen
vector
cours
like
lead
impair
viru
replic
revisit
tradit
method
viral
gene
express
exampl
use
condit
express
system
tetontetoff
may
open
door
new
gener
improv
viral
vector
viral
vector
also
use
applic
immun
infecti
diseas
exampl
prophylact
therapeut
cancer
vaccin
recent
studi
qiu
colleagu
describ
cytomegaloviru
vector
express
modifi
tumor
antigen
vaccin
candid
elicit
tumorspecif
tcell
respons
protect
mice
melanoma
anoth
promis
studi
use
live
attenu
polioviru
type
vaccin
glioblastoma
multiform
valid
concern
use
viral
vector
vaccin
possibl
vaccine
develop
vector
immun
result
reduc
immunogen
vaccin
use
combin
differ
vector
prime
booster
vaccin
found
overcom
issu
sever
exampl
literatur
describ
latter
strategi
eg
recombin
adenoviru
follow
mva
booster
regimen
dna
prime
follow
adenovir
booster
discuss
kreijtz
colleagu
excel
review
poxvir
vector
regulatori
challeng
overcom
implement
first
human
recombin
vaccin
candid
exist
vaccin
schedul
lead
major
improv
public
healthconceiv
sooner
rather
later
fast
track
recombin
vaccin
ebola
viru
diseas
would
pave
way
take
multipathogen
multival
vaccin
candid
bench
clinic
set
